| Original language | English (US) |
|---|---|
| Journal | Journal of the American Academy of Dermatology |
| DOIs | |
| State | Accepted/In press - 2021 |
ASJC Scopus subject areas
- Dermatology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Academy of Dermatology, 2021.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - A cross-sectional study of no-show rates and factors contributing to nonattendance at 3 academic pediatric dermatology centers in the United States
AU - Brown, Danielle N.
AU - Shields, Bridget E.
AU - Shrivastava, Samarth
AU - Welsh, Katie
AU - Mir, Adnan
AU - Wan, Joy
AU - Hynan, Linda S
AU - Arkin, Lisa
AU - Kovarik, Carrie
AU - Chong, Benjamin F.
N1 - Funding Information: Funding sources: This study was supported by internal funds from the University of Texas Southwestern Department of Dermatology. The sponsor was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Funding Information: Dr Chong is an investigator for Daavlin Corporation, Biogen Incorporated, and Pfizer Incorporated. He is a consultant for Celgene Corporation, Viela Bio, Bristol Meyers Squibb, EMD Serono, and Principia Biopharma. Dr Wan has received research funding from Pfizer , Inc, paid to the University of Pennsylvania . Dr Arkin has received research equipment from Candela, serves as an investigator for Celgene Corporation, and serves as a consultant to Regeneron and Amgen. Drs Brown, Shields, Mir, Hynan, and Kovarik and authors Srivastava and Welsh have no conflicts of interest to declare. Funding Information: Dr Chong is an investigator for Daavlin Corporation, Biogen Incorporated, and Pfizer Incorporated. He is a consultant for Celgene Corporation, Viela Bio, Bristol Meyers Squibb, EMD Serono, and Principia Biopharma. Dr Wan has received research funding from Pfizer, Inc, paid to the University of Pennsylvania. Dr Arkin has received research equipment from Candela, serves as an investigator for Celgene Corporation, and serves as a consultant to Regeneron and Amgen. Drs Brown, Shields, Mir, Hynan, and Kovarik and authors Srivastava and Welsh have no conflicts of interest to declare. Funding sources: This study was supported by internal funds from the University of Texas Southwestern Department of Dermatology. The sponsor was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
PY - 2021
Y1 - 2021
UR - http://www.scopus.com/inward/record.url?scp=85107449917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107449917&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2021.04.074
DO - 10.1016/j.jaad.2021.04.074
M3 - Article
C2 - 33932534
AN - SCOPUS:85107449917
SN - 0190-9622
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
ER -